<p>The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled "Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples.</p>

MP2PRT: Identification of Genetic Changes Associated with Relapse and/or    Adaptive Resistance in Patients Registered as Favorable Histology    Wilms Tumor on AREN03B2

Wilms Tumor study on CRDC (84 participants)

phs001965 — MP2PRT: Identification of Genetic Changes Associated with Relapse and/or    Adaptive Resistance in Patients Registered as Favorable Histology    Wilms Tumor on AREN03B2

MP2PRT: Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2

Description

Applying For Access

Summary